Between 2000 and 2010, the greatest production was from Marabá and Pau dArco, Pará, and the Paraná Basin, Rio Grande do Sul, Brazil; Sandoval, Santa Cruz, Bolivia; Artigas, Uruguay; Kalomo, Zambia; and Thunder Bay, Ontario. Lesser amounts are found in many other locations in Africa, Brazil, Spain, Argentina, Russia, Afghanistan, South Korea, Mexico, and the United States. Amethyst is produced in abundance in the state of Rio Grande do Sul in Brazil where it occurs in large geodes within volcanic rocks. Many of the hollow agates of southwestern Brazil and Uruguay contain a crop of amethyst crystals in the interior. Artigas, Uruguay and neighboring Brazilian state Rio Grande do Sul are large world producers, with lesser quantities mined in Minas Gerais and Bahia states. Amethyst is also found and mined in South Korea. The large opencast amethyst vein at Maissau, Lower Austria, was historically important, but is no longer included among significant producers. Much fine amethyst comes from Russia, especially near Mursinka in the Ekaterinburg district, where it occurs in drusy cavities in granitic rocks. Amethyst was historically mined in many localities in south India, though these are no longer significant producers. One of the largest global amethyst producers is Zambia in southern Africa with an annual production of about 1000 tons.Amethyst occurs at many localities in the United States.
Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin releasing hormone agonist (GnRH agonist). Structurally, it is a decapeptide. It is the natural GnRH decapeptide with two substitutions to inhibit rapid degradation. Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner. This causes the disruption of the endogenous hormonal feedback systems, resulting in the down-regulation of testosterone and estrogen production. It was patented in 1976 and approved for medical use in 1987. It is on the World Health Organizations List of Essential Medicines. Medical uses
Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri-menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transgender people and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot. Goserelin is administered by subcutaneous injection as an implant every 28 days for the duration of treatment. Side effects
Goserelin may cause a temporary increase in bone pain and symptoms of prostatic cancer during the first few weeks of treatment.